Rongrui Tang1, Jiantao Shi1, Xuegang Li1, Yongjie Zou2, Long Wang1, Yujie Chen1, Rubin Yan3, Boyuan Gao1, Hua Feng4. 1. Department of Neurosurgery, Southwest Hospital, Army Medical University, Chongqing, China. 2. Department of Neurosurgery, No. 184 of PLA Hospital, Yingtan, China. 3. Department of Rehabilitation, Southwest Hospital, Army Medical University, Chongqing, China. 4. Department of Neurosurgery, Southwest Hospital, Army Medical University, Chongqing, China. Electronic address: fenghua201818@aliyun.com.
Abstract
OBJECTIVE: To investigate the effects of atorvastatin on the surgical treatment of patients with chronic subdural hematoma (CSDH). METHODS: Our retrospective study included 245 consecutive adult patients undergoing burr-hole craniotomy for CSDH. Data included baseline characteristics and recurrence, postoperative complications, and mortality. Univariate and multivariate regression models analyzed the association between administration of atorvastatin perioperatively and recurrence rates. RESULTS: Multivariate analysis showed perioperative atorvastatin administration (odds ratio [OR] 0.336; P = 0.039), diabetes mellitus (OR 3.949, P = 0.010), and GCS of 15 preoperatively (OR 0.197; P = 0.020) to be significantly related to recurrence risk. Postoperative complications and mortality did not significantly differ between patients with and those without atorvastatin therapy. CONCLUSIONS: Our findings demonstrate that the administration of atorvastatin perioperatively is associated with a lower risk of CSDH recurrence rate. The use of atorvastatin perioperatively was not associated with higher rates of morbidity or mortality.
OBJECTIVE: To investigate the effects of atorvastatin on the surgical treatment of patients with chronic subdural hematoma (CSDH). METHODS: Our retrospective study included 245 consecutive adult patients undergoing burr-hole craniotomy for CSDH. Data included baseline characteristics and recurrence, postoperative complications, and mortality. Univariate and multivariate regression models analyzed the association between administration of atorvastatin perioperatively and recurrence rates. RESULTS: Multivariate analysis showed perioperative atorvastatin administration (odds ratio [OR] 0.336; P = 0.039), diabetes mellitus (OR 3.949, P = 0.010), and GCS of 15 preoperatively (OR 0.197; P = 0.020) to be significantly related to recurrence risk. Postoperative complications and mortality did not significantly differ between patients with and those without atorvastatin therapy. CONCLUSIONS: Our findings demonstrate that the administration of atorvastatin perioperatively is associated with a lower risk of CSDH recurrence rate. The use of atorvastatin perioperatively was not associated with higher rates of morbidity or mortality.
Authors: Rong Cai Jiang; Dong Wang; Shi Guang Zhao; Ren Zhi Wang; De Zhi Kang; Xin Gen Zhu; Zong Mao Zhao; Jun Ji Wei; Ying Huang; Yan Qu; Xiao Chuan Sun; Hong Ming Ji; Xiao Chun Jiang; Jin Fang Liu; Xi De Zhu; Jian Jun Wang; Ye Tian; Chuang Gao; Hui Jie Wei; Shu Zhang; Wei Quan; Shu Yuan Yue; Ping Lei; Xian Li; Li Li Song; Craig S Anderson; Jian Ning Zhang Journal: Trials Date: 2021-12-11 Impact factor: 2.279
Authors: Bradley S Guidry; Katherine A Kelly; Aaron M Yengo-Kahn; Matthews Lan; Alan R Tang; Silky Chotai; Peter Morone; Patrick D Kelly Journal: World Neurosurg Date: 2021-02-18 Impact factor: 2.104